BMJ Open Different doses of prucalopride in treating chronic idiopathic constipation: a meta-analysis and Bayesian analysis

Tao Yang ¹, Kaili Wang,² Yibo Cao,³ Jianxia Wen,⁴ Shizhang Wei,⁵ Haotian Li,⁵ Xiangdong Yang,⁶ Tianbao Xiao⁷

To cite: Yang T, Wang K, Cao Y, *et al.* Different doses of prucalopride in treating chronic idiopathic constipation: a meta-analysis and Bayesian analysis. *BMJ Open* 2021;**11**:e039461. doi:10.1136/bmjopen-2020-039461

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2020-039461>).

SW and HL contributed equally.

Received 17 April 2020

Revised 19 January 2021

Accepted 31 January 2021

ABSTRACT

Objective This study aims to explore the incremental benefit of different doses of prucalopride in treating chronic idiopathic constipation (CIC).

Methods PubMed, EMBASE, MEDLINE, Cochrane Library, Chinese Biomedical Database, China National Knowledge Infrastructure, VIP medicine information and Wanfang databases were comprehensively searched up to March 2020. Prospective trials with different doses of prucalopride versus placebo were selected. The frequency of spontaneous bowel movements (SBMs) per week and the treatment-emergent adverse events (TEAEs), such as headache, arrhythmia, diarrhoea, dizziness, nausea and vomiting, were first synthesised in a meta-analysis. The probability of optimal dose of prucalopride was then ranked by random-effects within Bayesian analysis.

Results 14 high-quality randomised controlled trials with 4328 patients were ultimately included. SBMs per week increased significantly after using 1 mg (OR: 2.40, 95% CI 1.32 to 4.37), 2 mg (OR: 2.55, 95% CI 1.93 to 3.36) and 4 mg (OR: 2.51, 95% CI 1.92 to 3.28) prucalopride. Bayesian analysis demonstrated 1 mg dose obtained the maximum SBMs per week (OR: 3.31, 95% credible interval 1.72 to 6.16, probability rank=0.70) indirectly compared with 2 mg and 4 mg doses. TEAEs were higher significantly in 2 mg (risk ratio (RR): 1.20, 95% CI 1.09 to 1.33) and 4 mg (RR: 1.14, 95% CI 1.07 to 1.22) prucalopride. The 1 mg dose did not reach statistical significance (RR: 1.17, 95% CI 0.94 to 1.44).

Conclusions The study concludes that 1 mg dose at commencement could be safer in treating CIC and that 2 mg prucalopride could be more efficacious in terms of SBMs per week outcome receiving.

PROSPERO registration number CRD42019136679.

INTRODUCTION

One of the most complicated disorders of the digestive system is chronic idiopathic constipation (CIC). The global prevalence of CIC in adults was estimated at 14% (95% CI 12% to 17%).¹ Age, particularly over 65 years, and female gender could be potential risk factors for increased prevalence.² CIC has the ability to curtail quality of life and increase psychological distress significantly.³ Furthermore, these harmful effects are inclined to be more widespread in patients with inability to

Strengths and limitations of this study

- This study applied comprehensive analysis methods, including meta-analysis, meta regression and Bayesian network analysis.
- This study confirms that there is no incremental benefit in prucalopride application and that 1 mg dose could be safer in treating chronic idiopathic constipation.
- Intention-to-treat analysis missing in many original studies may result in assessment bias.
- Undetected bias and methodological limitations could de-escalate the robustness of our results.
- The total number of patients in each dose group is small and this could contribute to an uncertain and controversial conclusion.

coordinate bowel movements than in patients with constipation with slow transition.⁴ A community survey about spending in CIC management demonstrates this annoying disease enormously increases social and economic burden.^{5 6}

Management methods are also hard and arduous strikingly for both gastrointestinal doctors and surgeons worldwide. Although laxatives (both stimulant and osmotic) have been widely employed in clinical practice, evidence on long-term efficacy in clinical setting remains inadequate.⁷ Furthermore, the weakened gastrointestinal motility and impairment of the intestinal nervous system (INS) precipitate the occurrence of CIC evidently.⁸ Therefore plausible treatments for CIC are suggested to focus on the neurons in the INS and improve their physiological excitability.⁹ Although many novel pharmacological attempts have been made, such as cisapride, tegaserod and lubiprostone, 'these attempts failed to earn popularity among clinical physicians and surgeons and failed to be included as first-line treatments, possibly due to remarkable side effects, possibly due to remarkable side effects (eg, cardiovascular

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Professor Tianbao Xiao;
prof_xiaotianbao@163.com

problems). Prucalopride was then investigated in clinical trials.

Prucalopride, a highly selective serotonin 5-hydroxytryptamine 4 (5-HT₄) agonist, was introduced to the market in 2009. The pharmacological mechanism of prucalopride is to stimulate the receptors of 5-HT₄, which are diffusely concentrated on the enteric neurons. The excitatory neurotransmitter acetylcholine is then released by the 5-HT₄ agonists and promotes mucosal secretion.¹⁰ Prucalopride has been advocated by the US Food and Drug Administration and the European Union for symptomatic treatment of CIC, especially in patients who have failed to adequately achieve symptom relief following stimulant or osmotic laxatives.¹¹ Previous randomised controlled trials (RCTs) have reported prucalopride doses of 0.5 mg, 1 mg, 2 mg and 4 mg compared with placebo accelerated colonic transit and spontaneous bowel movements (SBMs) per week prominently.^{12–15} However, there are rare guidelines or expert opinions to explore the incremental benefit of prucalopride. The administration of doses in clinical practice is empirical in most cases.¹⁶ It remains a conundrum whether dose-dependent relationship exists in using prucalopride.

This article attempts to define the clinical usefulness and safety of different doses of prucalopride in treating patients with CIC. We intend to provide the optimal dose of prucalopride for gastrointestinal physicians in clinical work and employed both pairwise meta-analysis and Bayesian analysis to address these problems as much as possible.

MATERIALS AND METHODS

Patient and public involvement

No patients were involved.

Protocol registration

We have registered this protocol in PROSPERO (International Prospective Register of Systematic Reviews) in May 2019 (<https://www.crd.york.ac.uk/PROSPERO>).

Eligibility criteria

The Cochrane Handbook for Systematic Reviews of Interventions and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement¹⁷ were used in this study. Studies that meet the following inclusion criteria were included: (1) the design of the study was a prospectively randomised controlled trial; (2) CIC was histologically confirmed; and (3) at least one of the investigated outcomes were reported in the original research. Exclusion criteria were as follows: (1) irrelevant studies and duplicate literature; (2) unavailable data in the literature; and (3) letters, reviews, comments, case reports and meta-analyses.

Search methodology

PubMed, EMBASE, MEDLINE, Cochrane Library, Chinese Biomedical Database, China National Knowledge

Infrastructure, VIP medicine information system and Wanfang electronic databases were comprehensively searched up to March 2020. The search terms were a combination of medical subject headings (MeSH) terms and the following free words: (constipation/chronic constipation/functional constipation) and (prucalopride/Resolor) and (random/randomized/RCTs/clinical trial). In addition, we manually searched for other potential and relevant references. There were no limitations in the language of all publications. Taking the PubMed database as an example, the search strategies are as follows:

- ▶ #1 constipation (MeSH).
- ▶ #2 constipation* af.
- ▶ #3 chronic constipation af.
- ▶ #4 functional constipation af.
- ▶ #5 #1 OR #2 OR #3 OR #4.
- ▶ #6 prucalopride (MeSH).
- ▶ #7 prucalopride af.
- ▶ #8 Resolor af.
- ▶ #9 #6 OR #7 OR #8.
- ▶ #10 #5 AND #9.
- ▶ #11 random* af.
- ▶ #12 #10 AND #11.

Study selection

Two investigators (TY and LKW) filtered the original studies independently. If the literature meets the eligibility criteria, the two investigators will further read the full text to screen the study. Any discrepancies were addressed by discussion or third party consensus.

Data extraction and analysis

All data were collected independently by two investigators (TY and BYC) from eligible RCTs using a standardised form. The following information was extracted: (1) study identification, including author name and publication year; (2) country where the study was conducted; (3) study subjects, number of participants and male to female ratio; (4) settings of trial arms and specific dose of prucalopride; (5) the primary outcome was SBMs per week, while the secondary outcome was treatment-emergent adverse events (TEAEs), defined as the total complications following prucalopride application, including headache, diarrhoea, dizziness, nausea, vomiting and so on, and were collectively reported in original trials and diagnosed using the same criteria. If insufficient details were reported, the authors were contacted for further information. Disagreements between two investigators were addressed by discussion and consensus.

Quality assessment

The Cochrane Collaboration's tool for assessing risk of bias and the Jadad scoring system¹⁸ were employed for quality evaluation. Randomisation, double blinding and dropout/withdrawal management were the main components of the Jadad scale. Any disagreements during

assessment were resolved by iteration, discussion and consensus.

Statistical analysis

Traditional pairwise meta-analysis with STATA

All original data were performed using STATA V.13.0 software for Windows. Q test and I^2 test were used to evaluate heterogeneity before pooled effects. The fixed-effect and random-effect models were based on the result of Q test and I^2 test. A fixed-effect model was adopted if I^2 was $<50\%$ and $p>0.1$. Otherwise, a random-effect model was chosen. For the outcomes, the proportion of patients reaching SBMs per week was set as the dichotomous variable, and the pooled analysis of SBMs was expressed as unadjusted OR. The TEAE was also a dichotomous variable, and we intend to apply risk ratio (RR) for synthesised effect. The 95% CI was calculated simultaneously within pooled OR and RR. Possible sources of heterogeneity were explored by meta-regression performed via a fixed-effect model; the restricted maximum likelihood (REML) estimation method proposed by Harbord *et al*¹⁹ was applied in meta-regression. Sensitivity analysis was carried out by omitting each trial one by one. Possible publication bias was determined by Egger's regression asymmetry test.²⁰ Meanwhile, contour-enhanced funnel plot was applied to distinguish detailed reasons for publication bias.²¹

Optimal dose of prucalopride ranked by Bayesian analysis

Bayesian framework provided a multiple-treatment meta-analysis model because it allows a feasible and practical estimation of direct and indirect comparisons based on probabilities, ranks or predictions.^{22 23} In the current study, different doses of prucalopride (1 mg, 2 mg and 4mg) and placebo were set as individual treatment groups. A random-effects approach was applied within a Bayesian framework with the GeMTC package in R (V.3.6.0). The Markov chain Monte Carlo method was used for pooled estimates. To achieve posterior distribution, three independent Markov chains were run simultaneously. Running for 20000 adaptations and 100000 updates per chain, the updating frequency of chain per one update was set as 10. Running lengths were extended if the Markov chains had not converged.²⁴ Probabilities of being superior were obtained from the posterior distribution. Ranks were obtained according to the estimated OR and RR. After posterior distributions were ensured, 95% credible interval (CrI) was derived from the 2.5th and 97.5th percentiles. The probability of the optimal dose of prucalopride was ranked using the surface under the cumulative ranking (SUCRA), which ranges between 0% and 100%.²² A parameter to rank different doses of prucalopride based on their probability of ranking first, second or third was used.

Figure 1 Flow chart presenting the selection process of studies, according to the PRISMA guidelines. CBM, Chinese Biomedical Database; CNKI, China National Knowledge Infrastructure; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

RESULTS

Study selection outcome

There were 532 relevant articles retrieved ultimately, among which 168 were duplicate articles. In total, 202 studies were excluded by title and abstract screening due to the studies being reviews, conference abstracts, animal experiments and case reports; this resulted in 162 articles. After examining the abstracts and full texts, 148 articles were further excluded. The meta-analysis finally included 14 studies^{13–15 25–35} that fulfilled the inclusion criteria (figure 1).

Study characteristics

In total, 4328 patients were included in the 14 studies.^{13–15 25–35} The mean sample size was 309 participants, ranging between 37²⁷ and 713¹⁵ patients. Table 1 displays the main characteristics of the 14 studies. Overall, 14 studies were published between 2001 and 2015 years, and 12 studies^{13–15 25–30 33–35} were conducted in Western countries and 2 in Asian countries.^{31 32} With respect to the treatment protocols, seven trials^{26 28 31–35} had one-arm design, five trials^{13 15 25 27 30} had two-arm setting, and two trials^{14 29} had three-arm design. One trial²⁹ used 0.5 mg prucalopride (PRU) versus placebo, 1 mg prucalopride was applied in 4 trials,^{14 26 27 29} 12 trials^{13–15 25 27 29–35} employed 2 mg prucalopride versus placebo, and 6 trials^{13–15 25 28 30} made use of 4 mg prucalopride versus placebo. There were diverse durations, ranging from 1 to 24 weeks. To retrieve data and combine outcomes consistently, our study analysed SBMs per week and total TEAEs after using 1 mg, 2 mg and 4 mg doses of prucalopride.

Table 1 Main information of the studies included in the meta-analysis

Study identification	Publication year	Region	Total patients (n)	M/F (n)		Treatment protocols	Treatment duration (weeks)	Clinical endpoints
				M	F			
Bouras <i>et al</i> ²⁵	2001	USA	40	4	36	2 mg vs placebo 4 mg vs placebo	1	Colonic transit time, gastric emptying, small bowel transit time and adverse events.
Emmanuel <i>et al</i> ²⁶	2002	UK	74	NR		1 mg vs placebo	4	Whole gut transit time, HR-QOL, orofacial transit time, rectal sensitivity and psychological state.
Sloots <i>et al</i> ²⁷	2002	The Netherlands	37	2	35	1 mg vs placebo 2 mg vs placebo	10	Colonic transit time, bowel diary, anorectal function, safety and tolerability.
Coremans <i>et al</i> ²⁸	2003	Belgium	53	1	52	4 mg vs placebo	4	Visual analogue scale, gut transit time, bowel function, safety and tolerability.
Camilleri <i>et al</i> ¹³	2008	USA, Belgium	620	75	545	2 mg vs placebo 4 mg vs placebo	12	SBMs/week, HR-QOL and safety.
Camilleri <i>et al</i> ²⁹	2009	USA	89	24	65	0.5 mg vs placebo 1 mg vs placebo 2 mg vs placebo	4	Pharmacokinetics, adverse events and ECG changes.
Quigley <i>et al</i> ³⁰	2009	Ireland	641	86	555	2 mg vs placebo 4 mg vs placebo	12	SBMs/week, HR-QOL, safety and tolerability.
Tack <i>et al</i> ¹⁵	2009	Belgium	713	66	650	2 mg vs placebo 4 mg vs placebo	12	SBMs/week, HR-QOL and safety.
Müller-Lissner <i>et al</i> ¹⁴	2010	Germany	303	92	211	1 mg vs placebo 2 mg vs placebo 4 mg vs placebo	4	SBMs/week, bowel movements, HR-QOL and safety.
Ke <i>et al</i> ³¹	2012	China, Korea	501	51	450	2 mg vs placebo	12	SBMs/week, HR-QOL, safety and adverse events.
Zou <i>et al</i> ³²	2012	China	313	36	277	2 mg vs placebo	12	SBMs/week, HR-QOL and safety.
Mugie <i>et al</i> ³³	2014	Europe (multicentre)	213	95	118	2 mg vs placebo	8	SBMs/week, HR-QOL, safety and tolerability.
Piessevaux <i>et al</i> ³⁴	2015	Europe (multicentre)	361	53	308	2 mg vs placebo	24	SBMs/week, HR-QOL, bowel movement frequency, adverse events and safety.
Yiannakou <i>et al</i> ³⁵	2015	Europe (multicentre)	370	NR		2 mg vs placebo	12	SBMs/week, HR-QOL, adverse events and safety.

F, female; HR-QOL, health-related quality of life; M, male; NR, not reported; SBMs/week, spontaneous bowel movements per week.

Study quality assessment

Methodological quality assessment and outline of the 14 studies are presented in [figure 2A,B](#). Randomised sequence

generation and allocation concealment were identified adequately in all trials. These trials were placebo-controlled with either single or double blinding, except one study.²⁵

Figure 2 Methodological quality graph and summary of the included studies: (A) risk of bias summary; (B) risk of bias graph; and (C) Jadad scoring system.

Intention-to-treat (ITT) analysis was applied in nine trials.^{13–15 26 28 31 32 34 35} Incomplete outcomes were not detected in all studies. The assessment results of the Jadad scale are shown in [figure 2C](#). The mean Jadad score was 4.357 points (range 3–5 points) among the included trials. All included trials were of high methodological quality.

Results of meta-analysis

SBMs per week following different doses of prucalopride versus placebo

Heterogeneity was first examined before pooled analysis. Test results revealed there was no statistically significant heterogeneity in 1 mg ([figure 3A](#)), slight heterogeneity in 2 mg ($I^2=51\%$ and Q test $p=0.026$; [figure 3B](#)) and no significant heterogeneity in 4mg ($I^2<50\%$ and Q test $p>0.1$; [figure 3C](#)) prucalopride versus placebo. Thus, a fixed-effect model was applied for pooled analysis in 1 mg and 4mg groups. A random-effect model was selected for 2mg pooled analysis. In the pooled meta-analysis, the incidence of SBMs per week increased significantly after using 1 mg prucalopride ($Z=2.87$, $p=0.004$; OR=2.40, 95% CI 1.32 to 4.37; [figure 3A](#)), 2mg prucalopride ($Z=6.63$, $p=0.000$; OR=2.55, 95% CI 1.93 to 3.36; [figure 3B](#)) and 4mg prucalopride ($Z=6.73$, $p=0.000$; OR=2.51, 95% CI 1.92 to 3.28; [figure 3C](#)). The results demonstrated that prucalopride was able to improve SBMs per week endpoint

effectively and develop an effective pharmacotherapy in the management of CIC. The results of the pooled analysis are presented in [figure 3](#), along with OR.

TEAEs following different doses of prucalopride versus placebo

Before pooled analysis, heterogeneity across studies was tested conventionally. The results of the heterogeneity test revealed there was no statistically significant heterogeneity in 1 mg ([figure 4A](#)), moderate heterogeneity in 2mg ($I^2=60.5\%$ and Q test $p=0.005$; [figure 4B](#)) and no significant heterogeneity in 4mg ($I^2<50\%$ and Q test $p>0.1$; [figure 4C](#)) prucalopride versus placebo. Thus, a fixed-effect model was applied for pooled analysis in 1 mg and 4mg groups. A random-effect model was selected for 2mg pooled analysis. In the pooled meta-analysis, the results showed that the incidence of TEAEs increased significantly after using 2mg prucalopride ($Z=3.57$, $p=0.000$; RR: 1.20, 95% CI 1.09 to 1.33) and 4mg prucalopride ($Z=3.82$, $p=0.000$; RR: 1.14, 95% CI 1.07 to 1.22). Meanwhile, 1 mg prucalopride did not reach statistical significance after pooled analysis ($Z=1.42$, $p=0.154$; RR: 1.17, 95% CI 0.94 to 1.44). Findings are shown in [figure 4](#), along with RR.

Bayesian analysis for optimal dose of prucalopride

Bayesian methodology was used to determine the optimal dose of prucalopride in the treatment of CIC through multiple-treatment meta-analysis models. Different doses of prucalopride reported in order of SBMs per week and TEAEs ranked according to SUCRA are shown in [figure 5](#). We reported the consistency model results of SBMs per week and TEAEs after confirming there was no statistically significant inconsistency and the three Markov chains converged (potential scale reduction factor=1). SBMs per week and TEAEs of 1 mg, 2mg and 4mg prucalopride reached statistical significance compared with placebo. After statistical comparison, we revealed that 1 mg prucalopride demonstrated the maximum frequency of SBMs per week (OR: 3.31, 95% CrI 1.72 to 6.16, [table 2](#); probability rank=0.70, [figure 5A](#)) indirectly compared with 2 mg and 4mg prucalopride. In terms of TEAEs, 1 mg prucalopride also holds the highest incidence (RR: 1.72, 95% CrI 1.02 to 2.92, [table 2](#); probability rank=0.47, [figure 5B](#)) compared with 2mg and 4mg prucalopride indirectly. Meanwhile, 4mg prucalopride has the second probability sequence (probability rank=0.33; [figure 5B](#)).

Sensitivity analysis

We carried out sensitivity analysis to verify the robustness of our results. The results are shown in [figure 6](#). We performed sensitivity analysis via the leave-one-out procedure each time, and the outcomes of the sensitivity analysis showed that exclusion of any study did not significantly account for heterogeneity, demonstrating our results were robust to some extent.

Publication bias

Egger's test and contour-enhanced funnel plot were employed to assess potential publication bias. First,

Figure 3 Forest plot for SBMs per week following different doses of prucalopride. (A) 1 mg prucalopride vs placebo; (B) 2 mg prucalopride vs placebo; and (C) 4 mg prucalopride vs placebo. SBMs, spontaneous bowel movements.

Figure 4 Forest plot for TEAEs following different doses of prucalopride. (A) 1 mg prucalopride versus placebo; (B) 2 mg prucalopride versus placebo; and (C) 4 mg prucalopride versus placebo. RR, risk ratio; TEAEs, treatment-emergent adverse events.

Figure 5 Bayesian analysis of SBMs per week and TEAEs following different doses of prucalopride: (A) probability rank of SBMs per week and (B) probability rank of TEAEs. SBMs, spontaneous bowel movements; TEAEs, treatment-emergent adverse events.

Egger's test was applied to assess potential publication bias for pooled SBMs per week and TEAEs as the results are quantitative. The results of the Egger's test revealed there was no publication bias in both synthesised analysis ($p_{\text{SBMs per week}}=0.929$, $p_{\text{TEAEs}}=0.483$; figure 7A,B). Then, contour-enhanced funnel plot, which added conventional milestones in levels of statistical significance ($p<0.01$, $p<0.05$, $p<0.1$ or $p>0.1$) to funnel plots, was used to distinguish detailed reasons for publication bias. The results indicated many missing studies are of higher statistical significance ($p<0.01$; figure 7C,D), which suggested the origin of asymmetry may be more likely to be due to undetected factors rather than publication bias. Finally, we traced the original research again, speculating that studies with a small sample size and with ITT analysis missing in many studies may account for the undetected bias. These factors may have a potential impact on our conclusions.

Meta-regression analysis

Meta-regression was performed to assess the effect of underlying confounding factors on pooled effect estimation and to seek the sources of heterogeneity for SBMs per week and TEAEs following 2mg prucalopride. We premeditated the following covariates as potential factors: (1) different patient ethnicity (Asian and Western); (2) total sample size ($n\geq 200$ and $n<200$); (3) different courses

of taking prucalopride; and (4) ITT analysis used. Overall, univariate analysis indicated ethnicity in different regions had a significant influence on the results of 2mg prucalopride between SBMs per week ($p=0.020$; figure 8A and table 3) and TEAEs ($p=0.002$; figure 8B and table 3). The remaining three variables influenced neither the pooled effect of SBMs per week nor the TEAEs significantly. Multivariate meta-regression was then used to evaluate the impact of various covariates on the pooled effect of SBMs per week and TEAEs. For SBMs per week, four covariates did not affect the relationship between 2mg prucalopride and SBMs per week outcome ($p=0.058$; table 3) and the heterogeneity did not stem from this model. For TEAEs, multivariate analysis revealed that the relationship between 2mg prucalopride and the TEAE endpoint was influenced by the covariate of ethnicity in different regions ($p=0.017$; table 3), indicating the heterogeneity may originate from this covariate.

DISCUSSION

Overall, the findings of the current study acknowledge that patients with CIC can be treated with prucalopride efficaciously, whether 1 mg, 2 mg or 4 mg doses are used. The certainty of conclusion from the current study is mainly reflected in the following two aspects. First, the proportion of SBMs per week was employed as the cardinal endpoint in the current study for pooled meta-analysis. According to the definition of SBMs per week based on the Rome criteria, SBMs per week can incorporate anorectal assessments of rectal evacuation and subjective symptoms completely.^{36 37} In the current study, SBMs per week increased significantly after using 1 mg (OR=2.40, 95% CI 1.32 to 4.37), 2 mg (OR=2.55, 95% CI 1.93 to 3.36) and 4 mg (OR=2.51, 95% CI 1.92 to 3.28) prucalopride. The results demonstrated that patients with CIC may benefit from prucalopride using different doses. Second, additional indicators of CIC, such as the Patient Assessment of Constipation Quality of Life and the Patient Assessment of Constipation Symptoms, also got ameliorated according to original researches.^{13 30 33–35}

Table 2 Bayesian analysis of SBMs/week and TEAEs following different doses of prucalopride

1 mg	RR (95% CrI) 1.72 (1.02 to 2.92)	RR (95% CrI) 1.61 (1.28 to 2.06)	RR (95% CrI) 1.67 (1.23 to 2.40)
OR (95% CrI) 1.26 (0.66 to 2.40)	2 mg	RR (95% CrI) 1.03 (0.57 to 1.80)	RR (95% CrI) 0.97 (0.67 to 1.33)
OR (95% CrI) 1.27 (0.63 to 2.48)	OR (95% CrI) 1.00 (0.70 to 1.43)	4 mg	RR (95% CrI) 1.07 (0.63 to 1.82)
OR (95% CrI) 3.31 (1.72 to 6.16)	OR (95% CrI) 2.61 (1.98 to 3.43)	OR (95% CrI) 2.60 (1.80 to 3.73)	Placebo

Significant results are in bold.

■ Treatment; ■ SBMs/week, OR (95% CrI); ■ TEAEs, RR (95% CrI).

95% CrI, 95% credible interval; RR, risk ratio; SBMs/week, spontaneous bowel movements per week; TEAEs, treatment-emergent adverse events.

Figure 6 Sensitivity analysis for (A) spontaneous bowel movements per week and (B) treatment-emergent adverse events.

Third, a prospective, randomised, cross-over study with 2mg prucalopride versus polyethylene glycol 3350 + electrolytes (PEG3350) also demonstrated prucalopride had obvious advantages over PEG3350 in promoting high-amplitude propagating contractions in patients with CIC.³⁸ All supporting evidence mentioned above demonstrates prucalopride should be an effective pharmacotherapy in the management of CIC. We tried to provide the optimal dose of prucalopride in CIC management through Bayesian framework models. The results revealed that 1mg, 2mg and 4mg prucalopride reached statistical

significance compared with placebo, which is consistent with a previous pairwise meta-analysis. Moreover, we revealed 1mg prucalopride obtained the maximum frequency of SBMs per week (OR: 3.31, 95% CrI 1.72 to 6.16, probability rank=0.70) indirectly compared with 2mg and 4mg doses. A previous study showed prucalopride applied at 4mg dose in the experiment arm did not provide a dose-dependent benefit in SBMs per week over 2mg dose (4mg 28.4% vs 2mg 30.9%).¹³ Another study also failed to achieve higher frequency of SBMs per week with a dose of 4mg over the 2mg dose (4mg 24% vs 2mg

Figure 7 Publication bias assessment. (A) Egger's test for SBMs per week; (B) Egger's test for TEAEs; (C) contour-enhanced funnel plot for SBMs per week; and (D) contour-enhanced funnel plot for TEAEs. SBMs, spontaneous bowel movements; TEAEs, treatment-emergent adverse events.

Figure 8 Univariate meta-regression analysis: (A) spontaneous bowel movements per week of 2 mg prucalopride and (B) treatment-emergent adverse events of 2 mg prucalopride. RR, risk ratio.

24%).³⁰ Considering all these, we arrived at the conclusion that there is no incremental benefit in prucalopride application and that 1 mg dose could be safer in treating CIC.

TEAEs related to prucalopride consumption were evaluated in this meta-analysis. When reported, headache, nausea, diarrhoea and abdominal pain are the most common TEAEs following prucalopride consumption.^{13 15 29 30} However, the severity of these TEAEs was slight or mild mainly during the first 24 hours of taking and lasts ephemerally.^{13 30 39} Our findings revealed the incidence of TEAEs increased significantly after using 2 mg dose (RR: 1.20, 95% CI 1.09 to 1.33) and 4 mg dose (RR: 1.14, 95% CI 1.07 to 1.22). Meanwhile, the 1 mg dose did not reach statistical significance after pooled analysis (RR: 1.17, 95% CI 0.94 to 1.44). Bayesian framework analysis showed the 1 mg dose holds the highest incidence (RR: 1.72, 95% CrI 1.02 to 2.92, probability rank=0.47) compared with

the 2 mg and 4 mg doses indirectly. Meanwhile, the 4 mg dose has the second probability sequence (RR: 1.61, 95% CrI 1.28 to 2.06, probability rank=0.33) and the 2 mg dose ranked the lowest (RR: 1.67, 95% CrI 1.23 to 2.40, probability rank=0.2). Clearly, the probability rank of 1 mg, 2 mg and 4 mg doses is lower than 50%. TEAEs of 5-HT₄ receptor agonists have received considerable attention, particularly cardiovascular adverse events.^{29 40} An earlier study suggested that no consistent or clinically relevant TEAE divergences were noted in ECG components versus baseline and placebo groups, even in 88% of volunteers with a history of cardiovascular diseases.²⁹ A thorough QT study,⁴⁰ based on the ICH E14 guidance, also demonstrated no evidence of QT prolongation or proarrhythmic potential for prucalopride application. This evidence suggests prucalopride has good tolerance in cardiovascular system and overall TEAEs.

Table 3 Meta-regression analysis of 2 mg SBMs per week (OR) and TEAEs (RR)

Covariates	2mg SBMs per week, OR (11 studies)				2mg TEAEs, RR* (11 studies)			
	Coefficient	95% CI†	P value	Tau2	Coefficient	95% CI†	P value	Tau2
Univariate analysis								
Ethnicity in different regions	0.70	0.14 to 1.27	0.020	0.023	0.24	0.03 to 0.46	0.002	0.006
Total sample size	0.00	−0.001 to 0.004	0.332	0.095	0.08	−0.55 to 0.71	0.786	0.021
Courses of taking prucalopride	2.09	−1.01 to 5.20	0.144	0.025	0.14	−0.35 to 0.63	0.514	0.026
ITT analysis	0.10	−1.10 to 1.30	0.856	0.114	0.01	−0.37 to 0.38	0.953	0.024
Multivariate analysis								
Ethnicity in different regions	0.70	−0.03 to 1.45	0.058	NA	0.31	0.07 to 0.55	0.017	NA
Total sample size	0.00	−1.97 to 1.97	0.999	NA	0.37	−0.33 to 1.07	0.688	NA
Courses of taking prucalopride	−0.04	−0.34 to 0.25	0.723	NA	0.09	−0.03 to 0.22	0.108	NA
ITT analysis	0.05	−0.78 to 0.89	0.873	NA	−0.04	−0.25 to 0.18	0.688	NA
Omnibus test for moderators			0.897	0.051			0.108	0.003

Significant results are in bold.

ITT, intention-to-treat; NA, not applicable; RR, risk ratio; SBMs, spontaneous bowel movements; TEAEs, treatment-emergent adverse events.

The current study exerts more attention to the incremental benefit of prucalopride. Previous work has provided critical findings that prucalopride is able to treat CIC effectively with mild, transitory and slight by-effects.^{41–44} However, the dose-related trends in efficacy assessment and TEAEs have not been explored. In this study, the results revealed that there is no incremental benefit in prucalopride application and 1 mg dose is suggested to be given at commencement. Furthermore, clinical evidence from China with 313 samples³² was included in the current study. The study of Zou *et al.*³² could be an eventful supplement to current evidence and fill the gap in knowledge about use of prucalopride in China, even in the Asian region. Finally, the current study is the most extensive meta-analysis based on 14 well-designed RCTs with 4328 patients, providing more powerful evidence in favour of the integrated analysis.

Potential limitations of this integrated analysis should be considered. Fourteen included trials with variable duration (from 1 to 24 weeks) measured endpoints by different criteria, such as colonic transit time, rectal sensitivity, anorectal function and SBMs per week, increasing the risk of measurement bias. Meanwhile, undetected bias predicted by contour-enhanced funnel plot showed studies with a small sample size and with ITT analysis missing may account for potential bias. These factors may have a potential impact on our conclusions. Meta-regression by univariate and multivariate analyses found different patient ethnicities (Asian and Western) were a potential covariate causing moderate heterogeneity ($I^2=60.5\%$) and de-escalate the validity of the results of the current analysis.

All in all, this is the largest meta-analysis with 4328 patients from 14 high-quality RCTs and provides pivotal evidence that prucalopride given at 1 mg dose can manage CIC effectively. Furthermore, no incremental benefit was detected in prucalopride application. When accepting the conclusions of this study, the methodological limitations should be considered at the same time. It is widely recognised that CIC is a chronic disease of intestinal dysfunction and requires long-term medication, so more RCTs of larger scale and with longer-term efficacy assessments are needed to balance the risk–benefit profile of prucalopride in the treatment of CIC.

Author affiliations

¹College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China

²China Academy of Chinese Medical Sciences, Beijing, China

³The First Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang City, China

⁴Chengdu University of Traditional Chinese Medicine, Chengdu, China

⁵5th Medical Center of Chinese PLA General Hospital, Fengtai-Qu, China

⁶Chengdu Anorectal Hospital, Chengdu, China

⁷Guizhou University of Traditional Chinese Medicine, Guiyang City, China

Acknowledgements Our greatest acknowledgement goes to the authors who made detailed data available for this meta-analysis and all our colleagues in this study for their hard work.

Contributors TY, LKW and XJW performed the search and drafted the manuscript. TY and BYC performed the data extraction and analysed the data. TY, TX and DXJ designed the study and amended the original draft

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID ID

Tao Yang <http://orcid.org/0000-0002-5787-2542>

REFERENCES

- 1 Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. *Am J Gastroenterol* 2011;106:1582–91.
- 2 Talley NJ, Fleming KC, Evans JM, *et al.* Constipation in an elderly community: a study of prevalence and potential risk factors. *Am J Gastroenterol* 1996;91:19–25.
- 3 Chang L, Toner BB, Fukudo S, *et al.* Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. *Gastroenterology* 2006;130:1435–46.
- 4 Rao SSC, Tuteja AK, Vellema T, *et al.* Dysynergic defecation: demographics, symptoms, stool patterns, and quality of life. *J Clin Gastroenterol* 2004;38:680–5.
- 5 Singh G, Lingala V, Wang H, *et al.* Use of health care resources and cost of care for adults with constipation. *Clin Gastroenterol Hepatol* 2007;5:1053–8.
- 6 Guerin A, Carson RT, Lewis B, *et al.* The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population. *J Med Econ* 2014;17:577–86.
- 7 Jones MP, Talley NJ, Nuyts G, *et al.* Lack of objective evidence of efficacy of laxatives in chronic constipation. *Dig Dis Sci* 2002;47:2222–30.
- 8 Chen F, Yu Y, Wang P, *et al.* Brain-derived neurotrophic factor accelerates gut motility in slow-transit constipation. *Acta Physiol* 2014;212:226–38.
- 9 Wald A, Scarpignato C, Mueller-Lissner S, *et al.* A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. *Aliment Pharmacol Ther* 2008;28:917–30.
- 10 Quigley EMM, Neshatian L. Advancing treatment options for chronic idiopathic constipation. *Expert Opin Pharmacother* 2016;17:501–11.
- 11 Bassotti G, Usai Satta P, Bellini M. Prucalopride for the treatment of constipation: a view from 2015 and beyond. *Expert Rev Gastroenterol Hepatol* 2019;13:257–62.
- 12 Bouras EP, Camilleri M, Burton DD, *et al.* Selective stimulation of colonic transit by the benzofuran 5HT₄ agonist, prucalopride, in healthy humans. *Gut* 1999;44:682–6.
- 13 Camilleri M, Kerstens R, Rykx A, *et al.* A placebo-controlled trial of prucalopride for severe chronic constipation. *N Engl J Med* 2008;358:2344–54.
- 14 Müller-Lissner S, Rykx A, Kerstens R, *et al.* A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. *Neurogastroenterol Motil* 2010;22:991–e255.
- 15 Tack J, van Outryve M, Beyens G, *et al.* Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. *Gut* 2009;58:357–65.
- 16 Jiang C, Xu Q, Wen X, *et al.* Current developments in pharmacological therapeutics for chronic constipation. *Acta Pharm Sin B* 2015;5:300–9.
- 17 Moher D, Liberati A, Tetzlaff J, *et al.* Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.

- 18 Jadad AR, Moore RA, Carroll D, *et al.* Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996;17:1–12.
- 19 Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. *Stat Med* 2006;25:3443–57.
- 20 Egger M, Davey Smith G, Schneider M, *et al.* Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.
- 21 Peters JL, Sutton AJ, Jones DR, *et al.* Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. *J Clin Epidemiol* 2008;61:991–6.
- 22 Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. *J Clin Epidemiol* 2011;64:163–71.
- 23 Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. *Stat Med* 2004;23:3105–24.
- 24 Gelman A, Rubin DB. Markov chain Monte Carlo methods in biostatistics. *Stat Methods Med Res* 1996;5:339–55.
- 25 Bouras EP, Camilleri M, Burton DD, *et al.* Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. *Gastroenterology* 2001;120:354–60.
- 26 Emmanuel AV, Roy AJ, Nicholls TJ, *et al.* Prucalopride, a systemic enterokinetic, for the treatment of constipation. *Aliment Pharmacol Ther* 2002;16:1347–56.
- 27 Sloots CEJ, Poen AC, Kerstens R, *et al.* Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. *Aliment Pharmacol Ther* 2002;16:759–67.
- 28 Coremans G, Kerstens R, De Pauw M, *et al.* Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. *Digestion* 2003;67:82–9.
- 29 Camilleri M, Beyens G, Kerstens R, *et al.* Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. *Neurogastroenterol Motil* 2009;21:e117:1 256–e117.
- 30 Quigley EMM, Vandeplasche L, Kerstens R, *et al.* Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation—a 12-week, randomized, double-blind, placebo-controlled study. *Aliment Pharmacol Ther* 2009;29:315–28.
- 31 Ke M, Zou D, Yuan Y, *et al.* Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. *Neurogastroenterol Motil* 2012;24:999–e541.
- 32 Zou DW, MY K, Yuan YZ. Prucalopride in the treatment of Chinese patients with chronic constipation : a randomised, double-blind, placebo-controlled study. *Chin.J.Dig* 2012;32:847–51.
- 33 Mugie SM, Korczowski B, Bodi P, *et al.* Prucalopride is no more effective than placebo for children with functional constipation. *Gastroenterology* 2014;147:1285–95.
- 34 Piessevaux H, Corazziari E, Rey E, *et al.* A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride. *Neurogastroenterol Motil* 2015;27:805–15.
- 35 Yiannakou Y, Piessevaux H, Bouchoucha M, *et al.* A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation. *Am J Gastroenterol* 2015;110:741–8.
- 36 Rao SS, Bharucha AE, Chiarioni G, *et al.* Functional anorectal disorders. *Gastroenterology* 2016 doi:10.1053/j.gastro.2016.02.009
- 37 Mearin F, Lacy BE, Chang L. Bowel disorders. *Gastroenterology* 2016.
- 38 Miner PB, Camilleri M, Burton D, *et al.* Prucalopride induces high-amplitude propagating contractions in the colon of patients with chronic constipation: a randomized study. *Neurogastroenterol Motil* 2016;28:1341–8.
- 39 Poen AC, Felt-Bersma RJ, Van Dongen PA, *et al.* Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. *Aliment Pharmacol Ther* 1999;13:1493–7.
- 40 Mendzelevski B, Ausma J, Chanter DO, *et al.* Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study. *Br J Clin Pharmacol* 2012;73:203–9.
- 41 Cheng E. Efficacy of prucalopride in the treatment of chronic constipation: a systematic review and meta-analysis of randomized controlled trials. *Clin Gastroenterol Hepatol* 2012;10:329–30.
- 42 Shin A, Camilleri M, Kolar G, *et al.* Systematic review with meta-analysis: highly selective 5-HT₄ agonists (prucalopride, velusetrag or naronapride) in chronic constipation. *Aliment Pharmacol Ther* 2014;39:239–53.
- 43 Nelson AD, Camilleri M, Chirapongsathorn S, *et al.* Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis. *Gut* 2017;66:1611–22.
- 44 Sajid MS, Hebbar M, Baig MK, *et al.* Use of prucalopride for chronic constipation: a systematic review and meta-analysis of published randomized, controlled trials. *J Neurogastroenterol Motil* 2016;22:412–22.